iRadimed Corporation (NASDAQ:IRMD – Get Free Report) CEO Roger Susi sold 5,000 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $87.51, for a total value of $437,550.00. Following the sale, the chief executive officer directly owned 2,175,000 shares in the company, valued at $190,334,250. This represents a 0.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
iRadimed Trading Up 3.5%
iRadimed stock opened at $90.40 on Thursday. iRadimed Corporation has a twelve month low of $50.88 and a twelve month high of $107.90. The stock’s fifty day simple moving average is $93.03 and its 200-day simple moving average is $95.01. The firm has a market capitalization of $1.16 billion, a P/E ratio of 49.40 and a beta of 0.90.
iRadimed (NASDAQ:IRMD – Get Free Report) last posted its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The business had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Sell-side analysts predict that iRadimed Corporation will post 1.52 earnings per share for the current year.
iRadimed Dividend Announcement
Hedge Funds Weigh In On iRadimed
Several large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company boosted its stake in iRadimed by 48.5% in the first quarter. The Manufacturers Life Insurance Company now owns 3,933 shares of the medical equipment provider’s stock valued at $379,000 after acquiring an additional 1,284 shares in the last quarter. Quantinno Capital Management LP boosted its stake in iRadimed by 12.5% in the first quarter. Quantinno Capital Management LP now owns 3,482 shares of the medical equipment provider’s stock valued at $335,000 after acquiring an additional 387 shares in the last quarter. Lazard Asset Management LLC boosted its stake in iRadimed by 15.4% in the first quarter. Lazard Asset Management LLC now owns 48,914 shares of the medical equipment provider’s stock valued at $4,708,000 after acquiring an additional 6,524 shares in the last quarter. Aristides Capital LLC boosted its stake in iRadimed by 8.5% in the first quarter. Aristides Capital LLC now owns 30,083 shares of the medical equipment provider’s stock valued at $2,896,000 after acquiring an additional 2,349 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in iRadimed by 144.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 15,445 shares of the medical equipment provider’s stock valued at $1,487,000 after acquiring an additional 9,136 shares in the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.
Analyst Ratings Changes
Several research firms recently commented on IRMD. Freedom Capital raised iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Weiss Ratings raised iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 6th. Lake Street Capital reissued a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. Finally, Roth Mkm reissued a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, iRadimed has a consensus rating of “Buy” and a consensus price target of $120.00.
Check Out Our Latest Analysis on iRadimed
About iRadimed
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Featured Stories
- Five stocks we like better than iRadimed
- TJX Companies Fires on All Cylinders With 9% Revenue Growth
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
